Favipiravir (T-705)

Catalog No.S7975 Batch:S797505

Technical Data

Formula

C₅H₄FN₃O₂

Molecular Weight

157.1

CAS No.

259793-96-9

Solubility (25°C)*

In vitro

DMSO

31 mg/mL (197.32 mM)

Water

2 mg/mL (12.73 mM)

Ethanol

2 mg/mL (12.73 mM)

In vivo (Add solvents to the product individually and in order)

Clear solution	5% DMSO 1 95% Corn oil	1.55mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 31 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	1.55mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 31 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.

Targets

RNA-dependent RNA polymerase ^[1]

In vitro

Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. ^[1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. ^[2]

In vivo

In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. ^[1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. ^[3]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells Concentrations 1000 μg/mL Incubation Time 3 days Method The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 10³ cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO₂. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).
Animal Study:^{^[1]}	Animal Models Mice infected with influenza virus A/PR/8/34 Dosages 200 mg/kg/day Administration p.o.

Cell Assay:^{^[1]}

Cell lines
MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells
Concentrations
1000 μg/mL
Incubation Time
3 days
Method
The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 10³ cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO₂. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).

Animal Study:^{^[1]}

Animal Models
Mice infected with influenza virus A/PR/8/34
Dosages
200 mg/kg/day
Administration
p.o.

References

Customer Product Validation

: Data from [Data independently produced by , , Cell Physiol Biochem, 2018, 49(1):381-394]

: Data from [Data independently produced by , , Antiviral Res, 2017, 143:237-245]

Selleck's Favipiravir (T-705) has been cited by 22 publications

Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus [ J Med Virol, 2024, 96(1):e29372]	PubMed: 38235544
ヒト iPS 細胞由来心筋細胞を用いた慢性収縮毒性評価法の開発 [ Okayama University, 2023 , 10.18926/65391]	PubMed: none
Ebola virus VP35 hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association [ Nat Commun, 2022, 13(1):2256]	PubMed: 35474062
TRIM25 inhibits influenza A virus infection, destabilizes viral mRNA, but is redundant for activating the RIG-I pathway [ Nucleic Acids Res, 2022, gkac512]	PubMed: 35736141
In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus [ Antiviral Res, 2022, 199:105273]	PubMed: 35257725
Novel Antiviral Activity of Ethyl 3-Hydroxyhexanoate Against Coxsackievirus B Infection [ Front Microbiol, 2022, 13:875485]	PubMed: 35495645
Favipiravir induces oxidative stress and genotoxicity in cardiac and skin cells [ Toxicol Lett, 2022, 371:9-16]	PubMed: 36152797
Use of liquid chromatography-tandem mass spectrometry for foscarnet quantification in human serum and cerebrospinal fluid [ Rapid Commun Mass Spectrom, 2022, e9255]	PubMed: 35001441
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase [ Antiviral Res, 2021, S0166-3542(21)00068-1]	PubMed: 33894278
Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors [ mBio, 2021, 12(1)e02754-20]	PubMed: 33468688

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.